{"id":75564,"date":"2026-08-20T11:58:40","date_gmt":"2026-08-20T03:58:40","guid":{"rendered":"https:\/\/flcube.com\/?p=75564"},"modified":"2026-08-20T11:58:41","modified_gmt":"2026-08-20T03:58:41","slug":"jiangsu-hengrui-1h-2026-innovative-drug-sales-jump-16-4-to-rmb-8-8-billion-offset-generic-drag-as-rd-spending-climbs-19","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75564","title":{"rendered":"Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&amp;D Spending Climbs 19%"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/600276:SHA\">SHA: 600276<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1276:HKG\">HKG: 1276<\/a>) reported first\u2011half 2026 results showing <strong>total operating revenue of RMB 15.456 billion<\/strong>, down 1.94% year\u2011on\u2011year, while <strong>net profit attributable to shareholders rose 0.34% to RMB 4.465 billion<\/strong>. The standout: <strong>innovative drug sales reached RMB 8.809 billion<\/strong>, up 16.38% and now accounting for 63.16% of total pharmaceutical revenue, as China&#8217;s leading drugmaker deepens its pivot from generics toward innovation.<\/p>\n\n\n\n<h2 id=\"h-1h-2026-financial-highlights\" class=\"wp-block-heading\">1H 2026 Financial Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>1H 2026<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Operating Revenue<\/strong><\/td><td>RMB 15.456 bn<\/td><td><strong>\u20111.94%<\/strong><\/td><\/tr><tr><td><strong>Product Sales Revenue<\/strong><\/td><td>RMB 13.948 bn<\/td><td><strong>+1.87%<\/strong><\/td><\/tr><tr><td><strong>Net Profit (attributable)<\/strong><\/td><td>RMB 4.465 bn<\/td><td><strong>+0.34%<\/strong><\/td><\/tr><tr><td><strong>R&amp;D Investment<\/strong><\/td><td>RMB 4.605 bn<\/td><td><strong>+18.96%<\/strong><\/td><\/tr><tr><td><strong>\u2011 of which Expensed R&amp;D<\/strong><\/td><td>RMB 3.493 bn<\/td><td><strong>+8.21%<\/strong><\/td><\/tr><tr><td><strong>Innovative Drug Sales<\/strong><\/td><td>RMB 8.809 bn<\/td><td><strong>+16.38%<\/strong><\/td><\/tr><tr><td><strong>Generic Drug Sales<\/strong><\/td><td>RMB 5.139 bn<\/td><td><strong>\u201116.07%<\/strong><\/td><\/tr><tr><td><strong>Out\u2011licensing Revenue<\/strong><\/td><td>RMB 1.422 bn<\/td><td>vs. RMB 1.991 bn in 1H 2025<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-innovative-drug-mix-accelerates\" class=\"wp-block-heading\">Innovative Drug Mix Accelerates<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>1H 2026 Revenue<\/th><th>YoY<\/th><th>Share of Innovative Sales<\/th><\/tr><\/thead><tbody><tr><td><strong>Oncology Innovative Products<\/strong><\/td><td>RMB 6.265 bn<\/td><td><strong>+2.58%<\/strong><\/td><td><strong>71.11%<\/strong><\/td><\/tr><tr><td><strong>Non\u2011Oncology Innovative Products<\/strong><\/td><td>RMB 2.545 bn<\/td><td><strong>+73.97%<\/strong><\/td><td><strong>28.89%<\/strong><\/td><\/tr><tr><td><strong>Total Innovative Drugs<\/strong><\/td><td>RMB 8.809 bn<\/td><td><strong>+16.38%<\/strong><\/td><td>63.16% of total pharma sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>73.97% surge in non\u2011oncology innovative products<\/strong> signals successful diversification beyond Hengrui&#8217;s traditional oncology base, while innovative drugs now contribute nearly two\u2011thirds of pharmaceutical revenue \u2014 a structural shift in the company&#8217;s earnings mix.<\/p>\n\n\n\n<h2 id=\"h-generic-business-continues-managed-retreat\" class=\"wp-block-heading\">Generic Business Continues Managed Retreat<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Generic drug sales fell 16.07% to RMB 5.139 billion<\/strong>, pressured by national and regional <strong>centralized procurement (VBP) policies<\/strong>.<\/li>\n\n\n\n<li>Hengrui <strong>proactively scaled back resource allocation<\/strong> to these products; centralized\u2011procurement risk continued to be absorbed.<\/li>\n\n\n\n<li>Generics&#8217; share of total pharmaceutical sales dropped to <strong>36.84%<\/strong> from <strong>44.72%<\/strong> a year earlier.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-out-licensing-revenue-normalizes-after-high-base\" class=\"wp-block-heading\">Out\u2011Licensing Revenue Normalizes After High Base<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Out\u2011licensing collaboration revenue, now a <strong>routine operating line<\/strong>, totaled <strong>RMB 1.422 billion<\/strong> in 1H 2026.<\/li>\n\n\n\n<li>The figure primarily comprised <strong>RMB 1.176 billion recognized from the GSK collaboration<\/strong> based on progress of performance obligations, plus <strong>milestone payments from Braveheart Bio<\/strong> and others.<\/li>\n\n\n\n<li>The year\u2011earlier period&#8217;s RMB 1.991 billion reflected a <strong>high base from upfront payments<\/strong> \u2014 <strong>US$200 million from Merck &amp; Co., Inc.<\/strong> and <strong>US$75 million from IDEAYA Biosciences<\/strong> \u2014 recognized when performance obligations were fulfilled.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation Transition On Track:<\/strong> With R&amp;D spending up nearly 19% and innovative drugs at 63% of pharma sales, Hengrui is cementing its pivot from volume\u2011based generics to high\u2011margin innovation.<\/li>\n\n\n\n<li><strong>Diversification Payoff:<\/strong> Non\u2011oncology growth of 74% reduces reliance on a single therapeutic franchise and broadens the launch pipeline.<\/li>\n\n\n\n<li><strong>Deal Flow as Earnings Lever:<\/strong> Recurring out\u2011licensing income \u2014 GSK progress revenue plus milestones \u2014 adds a volatile but increasingly institutionalized revenue stream that investors will watch alongside organic growth.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Hengrui&#8217;s innovation transition, product mix, and out\u2011licensing pipeline. Actual results may differ due to risks including centralized\u2011procurement policy changes, regulatory outcomes, collaboration progress, and market competition.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/600276_20260820_9AU6.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260820_9AU6.\"><\/object><a id=\"wp-block-file--media-28b38013-a5c3-4506-8dbf-bf0ff1aa8f8b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/600276_20260820_9AU6.pdf\">600276_20260820_9AU6<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/600276_20260820_9AU6.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-28b38013-a5c3-4506-8dbf-bf0ff1aa8f8b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) reported first\u2011half 2026 results showing total&#8230;<\/p>\n","protected":false},"author":1,"featured_media":75567,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[27,2586,4228,852],"class_list":["post-75564","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&amp;D Spending Climbs 19% - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) reported first\u2011half 2026 results showing total operating revenue of RMB 15.456 billion, down 1.94% year\u2011on\u2011year, while net profit attributable to shareholders rose 0.34% to RMB 4.465 billion. The standout: innovative drug sales reached RMB 8.809 billion, up 16.38% and now accounting for 63.16% of total pharmaceutical revenue, as China&#039;s leading drugmaker deepens its pivot from generics toward innovation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75564\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&amp;D Spending Climbs 19%\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) reported first\u2011half 2026 results showing total operating revenue of RMB 15.456 billion, down 1.94% year\u2011on\u2011year, while net profit attributable to shareholders rose 0.34% to RMB 4.465 billion. The standout: innovative drug sales reached RMB 8.809 billion, up 16.38% and now accounting for 63.16% of total pharmaceutical revenue, as China&#039;s leading drugmaker deepens its pivot from generics toward innovation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75564\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-20T03:58:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-20T03:58:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2001.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75564#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75564\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&amp;D Spending Climbs 19%\",\"datePublished\":\"2026-08-20T03:58:40+00:00\",\"dateModified\":\"2026-08-20T03:58:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75564\"},\"wordCount\":459,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75564#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2001.webp\",\"keywords\":[\"Finanical Reports\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75564#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75564\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75564\",\"name\":\"Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&amp;D Spending Climbs 19% - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75564#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75564#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2001.webp\",\"datePublished\":\"2026-08-20T03:58:40+00:00\",\"dateModified\":\"2026-08-20T03:58:41+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) reported first\u2011half 2026 results showing total operating revenue of RMB 15.456 billion, down 1.94% year\u2011on\u2011year, while net profit attributable to shareholders rose 0.34% to RMB 4.465 billion. The standout: innovative drug sales reached RMB 8.809 billion, up 16.38% and now accounting for 63.16% of total pharmaceutical revenue, as China's leading drugmaker deepens its pivot from generics toward innovation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75564#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75564\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75564#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2001.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2001.webp\",\"width\":1080,\"height\":608,\"caption\":\"Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&D Spending Climbs 19%\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75564#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&amp;D Spending Climbs 19%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&amp;D Spending Climbs 19% - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) reported first\u2011half 2026 results showing total operating revenue of RMB 15.456 billion, down 1.94% year\u2011on\u2011year, while net profit attributable to shareholders rose 0.34% to RMB 4.465 billion. The standout: innovative drug sales reached RMB 8.809 billion, up 16.38% and now accounting for 63.16% of total pharmaceutical revenue, as China's leading drugmaker deepens its pivot from generics toward innovation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75564","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&amp;D Spending Climbs 19%","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) reported first\u2011half 2026 results showing total operating revenue of RMB 15.456 billion, down 1.94% year\u2011on\u2011year, while net profit attributable to shareholders rose 0.34% to RMB 4.465 billion. The standout: innovative drug sales reached RMB 8.809 billion, up 16.38% and now accounting for 63.16% of total pharmaceutical revenue, as China's leading drugmaker deepens its pivot from generics toward innovation.","og_url":"https:\/\/flcube.com\/?p=75564","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-20T03:58:40+00:00","article_modified_time":"2026-08-20T03:58:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2001.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75564#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75564"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&amp;D Spending Climbs 19%","datePublished":"2026-08-20T03:58:40+00:00","dateModified":"2026-08-20T03:58:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75564"},"wordCount":459,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=75564#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2001.webp","keywords":["Finanical Reports","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75564#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75564","url":"https:\/\/flcube.com\/?p=75564","name":"Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&amp;D Spending Climbs 19% - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=75564#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=75564#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2001.webp","datePublished":"2026-08-20T03:58:40+00:00","dateModified":"2026-08-20T03:58:41+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) reported first\u2011half 2026 results showing total operating revenue of RMB 15.456 billion, down 1.94% year\u2011on\u2011year, while net profit attributable to shareholders rose 0.34% to RMB 4.465 billion. The standout: innovative drug sales reached RMB 8.809 billion, up 16.38% and now accounting for 63.16% of total pharmaceutical revenue, as China's leading drugmaker deepens its pivot from generics toward innovation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75564#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75564"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=75564#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2001.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2001.webp","width":1080,"height":608,"caption":"Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&D Spending Climbs 19%"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75564#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&amp;D Spending Climbs 19%"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2001.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75564","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75564"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75564\/revisions"}],"predecessor-version":[{"id":75568,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75564\/revisions\/75568"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/75567"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75564"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75564"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75564"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}